ProPhase Labs, Inc. Increase (Decrease) in Income Taxes Receivable
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Income Taxes Receivable of $502.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2018-03-28
- ProPhase Labs, Inc. increase (decrease) in income taxes receivable for fiscal 2017 was $502.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|
| 2017-12-31 | $502.00K 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |